Saudi Arabia Hosts OIC Medicines Regulators Meeting in Riyadh

The Kingdom of Saudi Arabia, represented by the Saudi Food and Drug Authority (SFDA), is hosting the third meeting of the Heads of National Medicines Regulatory Authorities (NMRAs) of the Organization of Islamic Cooperation (OIC) member states in Riyadh. The two-day conference, taking place on December 17-18 at the SFDA headquarters, is held under the theme “Advancing Medicine Regulation and R&D Ecosystems: Pathways to Regulatory Maturity” and underscores Saudi Arabia’s leadership in fostering international health cooperation.

Context and Background

This high-level gathering brings together heads and representatives of NMRAs from OIC member states, along with participants from regional and international organizations. The meeting is chaired by SFDA CEO Dr. Hisham Aljadhey, who will lead discussions on enhancing the effectiveness of medicine regulation across the Islamic world. By sharing expertise and best practices, member states aim to ensure equitable access to safe, effective, and high-quality medicines for their populations.

Key Agenda and Objectives

Key items on the agenda include the implementation of the OIC’s action plan for fostering collaboration among NMRA representatives, strategies to promote regulatory harmonization and coordination, and advancing the regulation and localization of biotechnology. The meeting will also focus on building a robust research and development (R&D) ecosystem to support innovation in pharmaceuticals and vaccines. These efforts align closely with the Sustainable Development Goals (SDGs), particularly in safeguarding public health and safety.

International Impact and Collaboration

The meeting highlights the importance of collective action in addressing shared health challenges. By strengthening cooperation among national regulatory authorities, OIC member states can improve the efficiency of medicine approvals, reduce duplication of efforts, and accelerate access to critical treatments. Saudi Arabia’s role as host reflects its commitment to driving global health innovation and its growing influence in shaping regulatory standards that benefit millions across the Islamic world.

Vision 2030 Alignment

This initiative is a clear demonstration of Saudi Arabia’s dedication to Vision 2030, which prioritizes health sector transformation, innovation, and international collaboration. By advancing medicine regulation and R&D ecosystems, the Kingdom is helping to build a healthier future for its citizens and the broader OIC community, reinforcing its position as a hub for excellence in public health and a key contributor to global sustainable development.

20 Questions

Q1. What is the purpose of the third meeting of the OIC Heads of National Medicines Regulatory Authorities?

A1. The meeting aims to enhance cooperation among OIC member states on medicine regulation, foster regulatory harmonization, and promote equitable access to safe and effective medicines, aligning with global health goals.

Q2. Who is hosting the meeting, and where is it taking place?

A2. The meeting is hosted by the Saudi Food and Drug Authority (SFDA) in collaboration with the OIC, and it is being held at the SFDA headquarters in Riyadh, Saudi Arabia.

Q3. What is the theme of the meeting?

A3. The theme is “Advancing Medicine Regulation and R&D Ecosystems: Pathways to Regulatory Maturity,” focusing on improving regulatory frameworks and research capabilities across OIC nations.

Q4. When is the meeting scheduled to occur?

A4. The meeting takes place over two days, from December 17 to December 18, 2024, as confirmed by the Saudi Press Agency.

Q5. Who is chairing the meeting?

A5. The meeting is chaired by SFDA CEO Dr. Hisham Aljadhey, who leads discussions on medicine regulation and collaboration among regulatory authorities.

Q6. Which countries are participating in the meeting?

A6. Participants include heads and representatives of National Medicines Regulatory Authorities from OIC member states, along with regional and international organizations.

Q7. How does this meeting support the Sustainable Development Goals?

A7. The meeting focuses on safeguarding public health and safety, aligning with the Sustainable Development Goals by improving access to quality medicines and strengthening health systems.

Q8. What are the main topics on the agenda?

A8. Key topics include the OIC action plan for NMRA collaboration, regulatory harmonization, biotechnology regulation and localization, advancing R&D, and ensuring access to medicines and vaccines.

Q9. Why is regulatory harmonization important for OIC member states?

A9. Regulatory harmonization reduces duplication of efforts, speeds up approval processes, and ensures consistent standards for medicine safety and efficacy across member states.

Q10. How does the meeting address biotechnology regulation?

A10. The meeting discusses strategies for regulating and localizing biotechnology to foster innovation and ensure safe, effective biotech products are available in OIC countries.

Q11. What role does Saudi Arabia play in global health initiatives?

A11. Saudi Arabia reaffirms its commitment to global health by hosting meetings that drive innovation and excellence in medicine regulation, contributing to healthier populations worldwide.

Q12. How does this meeting support the OIC’s action plan?

A12. The meeting implements the OIC’s action plan by fostering collaboration among NMRA representatives, sharing best practices, and coordinating regulatory efforts for better health outcomes.

Q13. What is the expected outcome of the meeting?

A13. Expected outcomes include enhanced cooperation, shared regulatory approaches, and a path toward regulatory maturity that benefits public health across OIC member states.

Q14. How does the meeting promote R&D ecosystems?

A14. The meeting highlights strategies to advance R&D ecosystems, encouraging innovation in pharmaceuticals and vaccines to address health challenges in the OIC region.

Q15. Are international organizations participating in the meeting?

A15. Yes, participants include representatives from regional and international organizations, facilitating broader collaboration and alignment with global regulatory standards.

Q16. How does this meeting align with Saudi Vision 2030?

A16. The meeting aligns with Vision 2030 by prioritizing health sector transformation, innovation, and international partnerships to enhance public health and economic diversification.

Q17. What is the significance of hosting the meeting in Riyadh?

A17. Hosting in Riyadh highlights Saudi Arabia’s leadership in health regulation and its role as a hub for international cooperation, supporting its Vision 2030 goals.

Q18. How will the meeting improve access to medicines in OIC countries?

A18. By harmonizing regulations and sharing expertise, the meeting aims to streamline approval processes and ensure safe, effective medicines reach populations more quickly and equitably.

Q19. What is the role of Dr. Hisham Aljadhey in the meeting?

A19. As SFDA CEO, Dr. Hisham Aljadhey chairs the meeting, guiding discussions on regulatory maturity and collaboration to enhance medicine regulation across OIC member states.

Q20. How does the meeting contribute to public health safety?

A20. The meeting strengthens cooperation among regulatory authorities, ensuring consistent standards for medicine safety and efficacy, thereby protecting public health in OIC nations.

---